ImmunoPrecise Antibodies - IPA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 473.77%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.22
▼ -0.03 (-2.40%)

This chart shows the closing price for IPA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ImmunoPrecise Antibodies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPA

Analyst Price Target is $7.00
▲ +473.77% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ImmunoPrecise Antibodies in the last 3 months. The average price target is $7.00, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 473.77% upside from the last price of $1.22.

This chart shows the closing price for IPA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in ImmunoPrecise Antibodies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00N/A
3/15/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$5.00Low
9/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00Low
3/21/2023BenchmarkLower TargetSpeculative Buy$12.00 ➝ $7.00Low
3/17/2023HC WainwrightReiterated RatingBuy$9.00Low
12/2/2022HC WainwrightInitiated CoverageBuy$9.00Low
10/25/2021BenchmarkInitiated CoverageBuy$12.00Medium
2/9/2021Industrial Alliance SecuritiesDowngradeBuy ➝ HoldLow
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.92 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/25/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2024

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
ImmunoPrecise Antibodies logo
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.
Read More

Today's Range

Now: $1.22
Low: $1.22
High: $1.27

50 Day Range

MA: $1.58
Low: $1.22
High: $1.98

52 Week Range

Now: $1.22
Low: $0.94
High: $4.22

Volume

39,374 shs

Average Volume

494,851 shs

Market Capitalization

$32.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.09

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmunoPrecise Antibodies?

The following Wall Street sell-side analysts have issued research reports on ImmunoPrecise Antibodies in the last twelve months: Benchmark Co., and HC Wainwright.
View the latest analyst ratings for IPA.

What is the current price target for ImmunoPrecise Antibodies?

2 Wall Street analysts have set twelve-month price targets for ImmunoPrecise Antibodies in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 473.8%. HC Wainwright has the highest price target set, predicting IPA will reach $9.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $5.00 for ImmunoPrecise Antibodies in the next year.
View the latest price targets for IPA.

What is the current consensus analyst rating for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IPA will outperform the market and that investors should add to their positions of ImmunoPrecise Antibodies.
View the latest ratings for IPA.

What other companies compete with ImmunoPrecise Antibodies?

How do I contact ImmunoPrecise Antibodies' investor relations team?

The company's listed phone number is 250-483-0308 and its investor relations email address is [email protected]. The official website for ImmunoPrecise Antibodies is www.immunoprecise.com. Learn More about contacing ImmunoPrecise Antibodies investor relations.